SYNEK, Svatopluk and Petr VESELÝ. Intravitreal Bevacizumab with or without triamcinolone for refractory diabetic macular oedema. Collegium Antropologicum. Zagreb: Croatian Anthropological Society, 2011, vol. 35, No 3, p. 841-845. ISSN 0350-6134.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Intravitreal Bevacizumab with or without triamcinolone for refractory diabetic macular oedema
Name in Czech Intravitreální aplikace bevacizumabu s a bez triamcinolonu pro refrakterní diabetický makulární edém
Authors SYNEK, Svatopluk (203 Czech Republic, guarantor, belonging to the institution) and Petr VESELÝ (203 Czech Republic, belonging to the institution).
Edition Collegium Antropologicum, Zagreb, Croatian Anthropological Society, 2011, 0350-6134.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30200 3.2 Clinical medicine
Country of publisher Croatia
Confidentiality degree is not subject to a state or trade secret
Impact factor Impact factor: 0.614
RIV identification code RIV/00216224:14110/11:00053413
Organization unit Faculty of Medicine
UT WoS 000296214700032
Keywords (in Czech) Bevacizumab; Diabetic macular oedema; triamcinolone; intravitreal injection
Keywords in English Bevacizumab; Diabetický makulární edém; triamcinolone; intravitreal injection
Tags International impact
Changed by Changed by: Mgr. Michal Petr, učo 65024. Changed: 20/4/2012 15:09.
Abstract
We evaluate the effect of intravitreal injections of Bevacizumab (IVB) alone or combined with triamcinolone (IVT) in the first injection for treatment of refractory diabetic macular oedema (DME). Sixty eyes of sixty patients with refractory DME were included. Half of the receive injections of IVB (1.25 mg/0.05 ml) or combined IVB and IVT (1.25 mg/0.05 ml and 2 mg/0.05 ml respectively). The primary outcome measure was change in central macular thickness (CMT). Secondary outcome measures were change in best-corrected logMAR visual acuity (BCVA) and incidence of potential adverse events. Central macular thickness was reduced significantly in both the IVB and IVB/IVT groups. At week 24, CMT change compared to the baseline was 93.7 um (95% CI, 172.2 to 19.26) in the IVB group and 93.1 um (95% CI, 154.4 to 29.7) in the IVB/IVT group. There was not a significant difference between the IVB and the IVB/IVT groups. Improvement of BCVA was initiated at weeks 6 and 12 in the IVB/IVT and IVB groups respectively.
Abstract (in Czech)
sledovali jsme dvě skupiny nemocných, léčených itravitreálnlí aplikací bevacizumabu s a bez triamcinolonu pro refrakterní diabetický makulární edém. Terapeutický efekt jsme zjistili v obou skupinách, skupina s triamcinolonem měla dřívější návrat zrakových funkcí, při dlouhodobém sledování se však rozdíly mezi skupinami vyrovnaly.
PrintDisplayed: 2/5/2024 07:40